Last Updated on January 21, 2025 by The Health Master
Door Step Delivery
Download the notification G.S.R. 220 (E) dated 26-03-2020, the link is given below in the article: The All-India Organisation of Chemists and Druggists (AIOCD), representing 12.40 lakh chemists and distributors nationwide, has demanded the Central Government, to immediate revocation of a COVID-19 era notification that permitted door step delivery of medicines.
The AIOCD argues that this notification, G.S.R. 220 (E) dated 26-03-2020, is now being exploited by online platforms, posing a significant threat to public health.
Background of the Notification:
Issued in March 2020 during the peak of the COVID-19 pandemic, G.S.R. 220 (E) dated 26-03-2020 allowed for the door step delivery of medicines under specific conditions.
This relaxation was intended to ensure uninterrupted access to essential medications during movement restrictions.
However, certain crucial safeguards, such as the mandatory stamping of prescriptions for medicine sales (Rule 65), were temporarily suspended.
Misuse by Online Platforms:
AIOCD leaders, President J S Shinde and General Secretary Rajiv Singhal, have expressed deep concern over the misuse of this notification by online platforms.
These platforms, they claim, are now leveraging the order to facilitate unregulated home delivery of medicines without adhering to essential safety protocols.
Concerns Regarding Public Health:
This unregulated online sale of medicines raises serious concerns:
- Self-Medication: Easy access to medications without a valid prescription encourages self-medication, which can have detrimental health consequences.
- Drug Abuse: Uncontrolled access to medications increases the risk of drug abuse and dependence.
- Antimicrobial Resistance: The indiscriminate use of antibiotics and other medications can contribute to the rise of antimicrobial resistance, making infections harder to treat.
AIOCD’s Demands:
The AIOCD has made the following demands to the government:
- Immediate Revocation of G.S.R. 220 (E) dated 26-03-2020: With the pandemic largely under control, the emergency measures outlined in this notification are no longer justified.
- Strict Enforcement of Prescription Requirements: To ensure patient safety, the government must strictly enforce the requirement for a valid prescription for all medicine sales.
- Crackdown on Illegal Online Platforms: The government must take immediate action to curb the illegal online sale of medicines and prevent the unregulated distribution of pharmaceuticals.
In conclusion, the AIOCD’s stance underscores the critical importance of maintaining stringent regulations for the sale and distribution of medicines.
Unregulated access to pharmaceuticals poses a serious threat to public health and safety, and the government must take decisive action to address this issue.
-
What is G.S.R. 220 (E) dated 26-03-2020?
This is a government notification issued during the COVID-19 pandemic that allowed for the door step delivery of medicines.
-
Why is the AIOCD demanding the revocation of this notification?
The AIOCD believes that this notification is being misused by online platforms, leading to the unregulated sale of medicines.
-
What are the potential consequences of unregulated medicine sales?
Unregulated medicine sales can lead to self-medication, drug abuse, and the rise of antimicrobial resistance.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.
Related articles:
Door step delivery of medicines: Kerala
Door step delivery of medicines is allowed since March
Doorstep delivery of medicines during Covid-19 lockdown: Centre
Over the Counter (OTC) Drug Revolution: New List Coming Soon
NPPA revised Ceiling price of 13 scheduled formulations: December 2024
Key Notes on Revised Schedule M: Point No. 11 – Personnel
USFDA issued Form 483 with two observations to Aurobindo for API plant
NPPA fixed retail price of 65 formulations: December 2024
Key Notes on Revised Schedule M: Point No. 10 – Self Inspection
Medical Device recall: USFDA classifies recall of these catheters as ‘most serious’
NPPA: New Strategy to Curb Drug Price Hikes
Pharmexcil 2024 Elections: New Leadership for India’s Pharmaceutical Industry
Key Notes on Revised Schedule M: Point No. 9 – Production under Loan License
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
